STAT

What’s scary, and appealing, about real-world evidence

The idea of real-world evidence is energizing much of the health world. For the rest, it's terrifying.

Last week STAT senior writer Matthew Herper wrote a story about a collaboration between Flatiron Health and the Food and Drug Administration, and a vexing topic called real-world evidence, which basically means the integration of types of data beyond clinical trials into the drug approval process. (You can read that story here.)

On Tuesday, Herper held a . Here is an edited partial transcript (emphasis on partial — subscribers got to go ) on the topic, particularly the area of “synthetic controls,” which Herper called “the biggest idea, the most appealing, and the scariest.”

You’re reading a preview, subscribe to read more.

More from STAT

STAT1 min read
STAT+: Health Care Leaders Plot How To Expand Diversity In Clinical Trials
Experts gathered at the Milken Institute Global Conference this week to discussed potential strategies to expand diversity in clinical trials. Here are some of their big ideas.
STAT1 min read
STAT+: Senate Drug Shortage Bill Would Pay Hospitals Bonuses For Good Contracting Practices
A bipartisan Senate bill takes a new approach to persistent drug shortages: have Medicare pay bonuses to hospitals and physicians for contracting that ensures a steady supply.
STAT2 min readCrime & Violence
STAT+: Pharmalittle: We’re Reading About A Medicare Price-negotiation Ruling, Pharma’s Slipping Reputation, And More
A U.S. judge dealt a blow to two drugmakers challenging the authority for Medicare to negotiate the prices of prescription drugs.

Related Books & Audiobooks